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Abstract
Ornithine decarboxylase (ODC) is a ubiquitous enzyme that is conserved in all species from bacteria to humans. Mammalian
ODC is degraded by the proteasome in a ubiquitin-independent manner by direct binding to the antizyme (AZ). In contrast,
Trypanosoma brucei ODC has a low binding affinity toward AZ. In this study, we identified key amino acid residues that
govern the differential AZ binding affinity of human and Trypanosoma brucei ODC. Multiple sequence alignments of the
ODC putative AZ-binding site highlights several key amino acid residues that are different between the human and
Trypanosoma brucei ODC protein sequences, including residue 119, 124,125, 129, 136, 137 and 140 (the numbers is for
human ODC). We generated a septuple human ODC mutant protein where these seven bases were mutated to match the
Trypanosoma brucei ODC protein sequence. The septuple mutant protein was much less sensitive to AZ inhibition
compared to the WT protein, suggesting that these amino acid residues play a role in human ODC-AZ binding. Additional
experiments with sextuple mutants suggest that residue 137 plays a direct role in AZ binding, and residues 119 and 140
play secondary roles in AZ binding. The dissociation constants were also calculated to quantify the affinity of the ODC-AZ
binding interaction. The Kd value for the wild type ODC protein-AZ heterodimer ([ODC_WT]-AZ) is approximately 0.22 mM,
while the Kd value for the septuple mutant-AZ heterodimer ([ODC_7M]-AZ) is approximately 12.4 mM. The greater than 50-
fold increase in [ODC_7M]-AZ binding affinity shows that the ODC-7M enzyme has a much lower binding affinity toward AZ.
For the mutant proteins ODC_7M(-Q119H) and ODC_7M(-V137D), the Kd was 1.4 and 1.2 mM, respectively. These affinities
are 6-fold higher than the WT_ODC Kd, which suggests that residues 119 and 137 play a role in AZ binding.
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Introduction
Ornithine decarboxylase (ODC, EC 4.1.1.17) is a pyridoxal
59phosphate-dependent enzyme that catalyzes the decarboxylation
of ornithine to putrescine [1,2]. This reaction is the first and rate-
limiting reaction in polyamine biosynthesis [3,4], which is essential
for eukaryotic cell growth and differentiation [5–7]. Polyamines and
ODC play important roles in many biological functions, including
the cell cycle, cellular proliferation, differentiation, apoptosis and
embryonic development [8–17]. High levels of polyamines and
ODC have also beenassociated withhuman disease and a variety of
cancers [3,18–23]. Because the concentration of ODC and
polyamine is critical for cell proliferation [11], as well as during
the development of neoplastic disease [24–28], ODC is considered
to be an oncogenic enzyme. Regulation of ODC and polyamine
levels is a current target for therapeutic studies involving numerous
types of cancer [13,29–33].
ODC activity in vivo is highly regulated through several pathways
(reviewed in [3,6,18,19]). For instance, the ODC protein has a short
half-life and turns over very rapidly [34,35]. A majority of proteins
are degraded through ubiquitination, but ODC is degraded by the
proteasomeinaubiquitin-independentmannerviadirectbindingto
the antizyme protein (AZ), which is regulated by polyamines
[36–39]. AZ binds to ODC and promotes the dissociation of ODC
homodimers and then forms the AZ-ODC heterodimer which is
ultimately degraded by the 26S proteasome [3,19,40–42]. Several
studies have shown that 37 residues in the C-terminus of ODC are
important for degradation [41,43,44], and deletion of this region
stabilizes ODC, even in the presence of AZ [45]. Moreover,
additional studies have shown that residues 117–140 of ODC may
play a role in AZ binding, which induces a conformational change
in ODC that exposes the C-terminus and leads to recognition/
degradation by the 26S proteasome [35,36,46].
The ODC protein circulates as a homodimer, and dimer
formation is essential for enzyme activity [3,47,48]. The active site
is located at the dimer interface, which is formed by the N-
terminal domain of one subunit and the C-terminal domain of the
second subunit [47]. Disruption of the dimer interface causes a loss
of enzyme activity [42]. ODC can bind to AZ to form a
heterodimer, and the AZ residues Glu-161, Glu-164 and Glu-165
seem to allow, through electrostatic interactions, the binding
between of ODC to AZ to form a heterodimer [49]. The binding
of AZ with ODC causes the ODC dimer to dissociate and thus
inhibits ODC enzyme activity [3,42].
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The AZ mRNA transcript contains two overlapping open reading
frames (ORFs). As the cellular concentration of polyamines
increases, it induces a translational frame-shift of the AZ mRNA,
which produces a longer functional AZ protein [19,50–52].
Moreover, the cellular polyamines and polyamine transporter
are regulated by AZ. AZ not only inhibits ODC activity to
suppress polyamine production but also restrains polyamine
uptake and stimulates polyamine excretion, thus controlling
polyamine levels [38,53–55]. Through this mechanism, ODC
activity is down-regulated by AZ if polyamines are excessively
generated by ODC.
ODC is a ubiquitous enzyme that is conserved in all species
from bacteria to humans. The fatal human disease African
sleeping sickness is caused by the protozoan Trypanosoma brucei. The
disease is currently treated with an irreversible inhibitor, DFMO
(DL-a-difluoromethylornithine), which inhibits the Trypanosoma
brucei ODC enzyme (tODC) [56–58]. tODC is more stable than
hODC, and tODC lacks the C-terminus that appear to be
important for human ODC protein degradation [34,59]. Further-
more, tODC has a low binding affinity toward AZ and thus has a
long half-life in the Trypanosoma brucei [34]. Mutation of mouse
ODC residues 117–140 to match the tODC sequence disrupts
both AZ binding and in vivo regulation, suggesting that this
sequence within mouse ODC is important for AZ binding [34]. In
this paper, we identified several amino acid residues that influence
human ODC (hODC) binding to AZ. Sequence alignments of
residues 117–140 of the hODC and tODC proteins show that
there are seven non-conserved amino acid residues within this
region (Table 1). We therefore mutated these seven amino
acid residues in hODC to match the tODC sequence and
subsequently examined the binding affinity of the mutant human
ODC toward AZ.
Results and Discussion
Previous structural studies of human ODC suggest that residues
117–140 may be the putative AZ-binding site [34,60]. Mutation of
residues 117–140 in mouse ODC to match the tODC sequence
resulted in decreased binding affinity toward AZ, implying that
this region is important for AZ binding [34]. In this AZ-binding
region of ODC, some amino acid residues are diverse and they
may be the factors determining the differential AZ-binding affinity
among these organisms. We aligned and compared the protein
sequences of hODC and tODC and chose seven candidate
residues to further study based on the charge dissimilarities and
hydrophobicity (Table 1). The mutations that were made to the
human ODC protein are Q119H, A124R, N125D, Q129D,
E136V, V137D and M140E.
Analysis of AZ inhibition of the hODC septuple mutant
We initially simultaneously mutated all seven of these residues to
generate a septuple mutant hODC protein, which was named
ODC_7M (ODC_Q119H/A124R/N125D/Q129D/E136V/
V137D/M140E). For ODC_WT, the enzyme activity decreased
with increasing concentrations of AZ. At a molar ratio of 2:1
monomeric AZ to dimeric ODC, the ODC enzyme activity was
approximately 30% (Figure 1A, closed circles). In contrast, the
septuple ODCmutant wasmuchlesssensitiveto AZinhibition. At a
molar ratio of 1:1 AZ:ODC, the septuple ODC enzyme activity was
approximately 90% (Figure 1A, open circles), indicating that these
seven residues play a role in AZ binding and regulation of ODC
enzyme activity.
Analysis of AZ inhibition of hODC sextuple mutants
By using ODC_7M as the template, we generated ODC mutant
enzymes that had each possible combination of six point muta-
tions. We created 7 sextuple mutants: ODC_7M(-Q119H), ODC_
7M(-A124R), ODC_7M(-N125D), ODC_7M(-Q129D), ODC_7M
(-E136V), ODC_7M(-V137D) and ODC_7M(-M140E). For ODC_
7M(-Q119H), all of the residues were mutated except for Q119H
(ODC_A124R/N125D/Q129D/E136V/V137D/M140E). The pur-
pose of generating these sextuple mutants was to identify the
essential amino acid residue(s) that govern ODC-AZ binding.
The inhibitory plots for these sextuple mutants are also shown in
Figures 1. ODC_7M(-A124 R) and ODC_7M(-E136V) had a
pattern of inhibition that was similar to ODC_7M (Figure 1B).
These mutants were not significantly inhibited by AZ, which
suggests that AZ is no longer binding and that residues 124 and
136 alone do not play a major role in AZ inhibition/binding. The
ODC_7M(-N125D) and ODC_7M(-Q129D) enzymes were mod-
erately resistant to AZ inhibition (Figure 1C), indicating that
residues 125 and 129 may play a small role in AZ inhibition. The
ODC_7M(-Q119H), ODC_7M(-V137D) and ODC_7M(-M140E)
mutants had very little resistance to AZ inhibition (Figure 1D). This
is especially obvious for ODC_7M(-V137D), which had an
inhibition plot that is similar to ODC_WT, implying that residue
137 may be the most important amino acid residue involved in AZ
binding and inhibition. The inhibitory plots of ODC_7M(-Q119H)
and ODC_7M(-M140E) suggest that residues 119 and 140 may
play secondary roles in human ODC-AZ binding.
Analysis of AZ inhibition of hODC double and triple
mutants
To further confirm the significance of residues 119, 137 and 140
in AZ binding, double and triple hODC mutants were created.
The triple mutant ODC_Q119H/V137D/M140E had an
inhibitory plot that is very similar to ODC_7M (Figure 1E, closed
squares), again suggesting these three amino acid residues play a
role in ODC binding to AZ. However, the ODC_Q119H/V137D
double mutant was also resistant to AZ inhibition, similar to the
triple mutant (Figure 1E, open circles), which suggests that residues
Table 1. Amino acid residues at the putative AZ-binding site
of human ODC (hODC), Trypanosoma brucei ODC (tODC) and
human AZI (hAZI).
hODC tODC hAZI hODC tODC hAZI
Residue Non-conserved Residue Conserved
119 Q H Q 120 I I I
124 A R A 122 Y Y Y
125 N D K 123 A A A
129 Q D N 127 G G G
136 E V E 128 V V V
137 V D I 131 M M M
140 M E K 132 T T T
Residue Similar 133 F F C
121 K R K 134 D D D
126 N S V 138 E E E
130 M V I 139 L L L
135 S C N
doi:10.1371/journal.pone.0026835.t001
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ODC_Q119H/V137D/M140E, ODC_V137D/M140E displayed
moderate AZ inhibition (Figure 1E, open triangles); absence of the
Q119H mutation decreased the AZ inhibitory resistance. ODC_
Q119H/M140EdisplayedminorAZ-inhibitionresistance(Figure1E,
closed triangles), which again suggests that residue 137 plays a key
role in hODC binding to AZ.
Dissociation constant of the hODC-AZ heterodimer
To quantify the effect of hODC mutations on the AZ binding
affinity, dissociation constants (Kd) were determined for the human
WT and mutant ODC proteins (Table 2). Sedimentation velocity
(SV) experiments with increasing AZ concentrations were
performed, and the data were globally fitted to determine the
dissociation constant of the ODC-AZ heterodimer (Table 2).
Figure 2 shows the distribution plots of the WT and mutant ODC
proteins. In the absence of AZ, ODC formed a stable dimer with
an S-value of approximately 6; when AZ was present, ODC was
dissociated. The ODC dimer peak shifted left and an ODC-AZ
complex was formed, which had an S-value of approximately 4.1
(Figure 2A). The Kd value of the [ODC_WT]-AZ heterodimer is
approximately 0.22 mM, while the [ODC_7M]-AZ heterodimer
Kd is approximately 12.4 mM. The greater than 50-fold increase in
the [ODC_WT]-AZ complex Kd indicates that the ODC-7M
enzyme really has an extremely low binding affinity toward AZ.
The triple mutant ODC_Q119H/V137D/M140E had an AZ-
binding affinity that is similar to ODC_7M. The Kd for the
[ODC_Q119H/V137D/M140E]-AZ heterodimer was about
9.9 mM, which is approximately 45-fold greater than the
WT_ODC one. The Kd values for ODC_7M(-Q119H) and
ODC_7M(-V137D) were 1.4 and 1.2 mM, respectively, and are 6-
fold higher than the WT_ODC. These data again suggest that
residues 119 and 137 play a key role in AZ binding.
Kinetic properties of human WT and mutant ODC
enzymes
The kinetic parameters of the WT and mutant ODC enzymes
were determined (Table S1). There were no obvious differences in
Km for ornithine substrate and PLP cofactor; additionally, the kcat
values for the WT and mutant enzymes were similar. These data
suggest that the putative AZ-binding site mutations do not affect
ODC enzymatic activity and may not induce a significant change
in enzyme conformation.
Charge effect in the putative AZ-binding site for
differential AZ-binding affinity
Mutation of residues 117–140 in mouse ODC to mimic the
Trypanosoma brucei ODC protein sequence abolished AZ
binding [34], which suggests that several or all of these amino
acid residues play a role in AZ binding. Our data clearly show that
residues 137 and 119 in human ODC play key roles in AZ binding
and influence the differential AZ-binding affinity of hODC and
tODC. Mutation of Val137 to Asp and Gln119 to His (ODC_
Q119H/V137D) may introduce a new charge to the AZ-binding
element that may repel AZ and prevent binding. Whether Val137
and Gln119 in hODC directly contact with AZ or simply stabilize
the conformation in the AZ-binding site of hODC cannot be
clearly elucidated at this time. Crystal structural analysis of hODC-
AZ interaction may show the binding of these residues to their
counterparts in AZ, however, this complex structure is not
available.
Residues 125 and 129 are both aspartic acids, and residue 140 is
glutamic acid in tODC; however, in hODC these positions are
amino acid residues with neutral side chains (Table 1). Introduc-
tion of these negatively charged amino acid residues with the
mutant hODC decreases the binding affinity between ODC and
AZ. The structural superimposition of hODC and tODC
demonstrates a perfect overlapping with a RMSD value of 0.81,
and the Ca positioning highlights the conserved AZ-binding
element. The inability of tODC to bind AZ and the weak binding
affinity of the [ODC_7M]-AZ complex may result from the
mutated charged amino acid residues at positions 119, 125, 129,
137 and 140 of the ODC enzyme.
The putative AZ-binding residues of ODC
Sequence alignments at the putative AZ-binding site of hODC,
tODC and human antizyme inhibitor (hAZI) is shown in Table 1.
The AZI protein structure is homologous to ODC, and AZI
has a higher binding affinity toward AZ [42]. Gln119 is highly
conserved in all of the ODC and AZI enzymes, except in
trypanosomes, suggesting that residue 119 may be crucial for the
differential AZ-binding affinity between hODC and tODC but not
between ODC and AZI. In contrast, residues 125 and 140 are not
strictly conserved; in a majority of the ODC sequences, residue
125 is a neutral Asn or Ser and 140 is Met or Ser; however, in
tODC these residues are negatively charged Asp and Glu,
respectively, while in AZI, they are a positively charged Lys.
Our previous report has suggested that the differences in residues
125 and 140 between human ODC and AZI are responsible for
the differential AZ-binding affinities [61]. Here we suggest that
electrostatic effects are responsible for the differential AZ-binding
affinities among hODC, hAZI and tODC. Furthermore, residue
129 is Asn or Gln and residue 137 is Val or Ile in a majority of the
ODC and AZI sequences, while these residues are Asp in tODC.
Based on the sequence comparisons and the mutagenesis analyses,
we hypothesize that repulsive effect may occur in tODC-AZ
binding. The ODC_7M mutant, which has the tODC sequence
Figure 1. AZ inhibition of the wild type and ODC mutant proteins. A: inhibition plots for the ODC_WT and ODC_7M septuple enzymes; B:
inhibition plots for the ODC_7M(-A124R) and ODC_7M(-E136V) sextuple mutant enzymes; C: inhibition plots for the ODC_7M(-N125D) and ODC_7M(-
Q129D) sextuple mutant enzymes; D: inhibition plots for the ODC_7M(-Q119H), ODC_7M(-V137D) and ODC_7M(-M140E) sextuple mutant enzymes;
E: inhibition plots for the ODC_Q119H/V137D, ODC_Q119H/M140E, ODC_V137D/M140E and ODC_Q119H/V137D/M140E mutant enzymes. The
enzyme concentration was kept constant at 20 mg/mL, while the AZ concentration ranged from 0 to 28 mg/mL.
doi:10.1371/journal.pone.0026835.g001
Table 2. Dissociation constants of the human ODC-AZ
complex.
hODC-AZ complex Kd (mM)*
[ODC_WT]-AZ 0.2260.03
[ODC_Q119H/V137D/M140E]-AZ 9.9560.36
[ODC_7M]-AZ 12.4360.43
[ODC_7M(-Q119H)]-AZ 1.4260.02
[ODC_7M(-V137D)]-AZ 1.2060.02
*The Kd value was derived from global data fitting of the sedimentation velocity
at three different protein concentrations of AZ (0.03–0.09 mg/mL, Fig. 2). The
protein concentrations of human ODC were fixed at 0.3 mg/mL.
doi:10.1371/journal.pone.0026835.t002
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AZ-binding affinity than hODC, suggesting the differences in
charge properties of these residues play a key role in AZ-binding
affinity of ODC.
Materials and Methods
Site-directed mutagenesis
Site-directed mutagenesis was performed with a Quik-
Change
TM kit (Stratagene, USA) to generate plasmids with the
mutated human ODC (hODC). Purified hODC DNA was used as
the template, which was PCR amplified with high-fidelity Pfu
DNA polymerase and specific primers with the appropriate codon.
The primers with the desired mutations were between 25 to 45
bases in length, which is necessary for specific binding to the
template DNA. The sequence was amplified for 16–18 cycles. The
PCR products were then treated with DpnI to cleave the wild-type
hODC template. The mutant PCR amplicons were cloned into a
plasmid vector and transformed into XL-1 E. coli. The mutant
plasmid DNA sequence was confirmed by autosequencing.
Recombinant hODC expression and purification
Human ODC or AZ was sub-cloned into the pQE30 vector
(Qiagen, Hilden, Germany), which carries a N-terminal His6?Tag
sequence for purification. This ampicillin-resistant vector was
transformed into the JM109 strain of Escherichia coli. Recombinant
protein expression was induced with 1.0 mM isopropyl-1-thio-b-
D-galactoside (IPTG), and the cells were harvested at 25uC
overnight. The recombinant protein was purified with a Ni-NTA
Sepharose column (Sigma). The lysate-Ni-NTA mixture was
washed with buffer that contained 10 mM imidazole, 500 mM
NaCl and 30 mM Tris-HCl (pH 7.6). Recombinant ODC or AZ
was eluted with buffer comprised of 250 mM imidazole, 500 mM
NaCl, 2 mM b-mercaptoethanol and 30 mM Tris-HCl, pH 7.6.
The purified ODC enzyme was buffer-exchanged and concen-
trated with 30 mM Tris-HCl (pH 7.6) and 2 mM b-mercapto-
ethanol with a 30 kDa molecular weight cutoff centrifugal filter
device (Amicon Ultra-15, Millipore). The purified AZ protein was
buffer-exchanged and concentrated with 250 mM NaCl, 30 mM
Tris-HCl (pH 7.6) and 2 mM b-mercaptoethanol with a 10 kDa
cutoff centrifugal filter device. The protein purity was verified by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), and the protein concentration was determined with the
Bradford method [62].
ODC enzyme assays
The decarboxylation of ornithine by ODC was measured with a
CO2-L3K assay kit (DCL, Charlottetown, Canada) at 37uC. A
continuous measurement of ODC enzyme activity was coupled
with the decarboxylation of ornithine to the carboxylation of
phosphoenolpyruvate (PEP) to form oxaloacetate (OAA), which
becomes malate following NADH oxidation according to a
previously published protocol [42]. The assay reaction mixture
for spectrophotometry contained 30 mM Tris-HCl (pH 7.8),
10 mM ornithine, 0.2 mM PLP and 0.4 mL of CO2-L3K assay
buffer containing 12.5 mM phosphoenolpyruvate, 0.4 unit/mL
microbial phosphoenolpyruvate carboxylase, 4.1 units/mL mam-
malian malate dehydrogenase and 0.6 mM NADH analog in a
final volume of 0.5 mL. ODC enzyme was added to initiate the
reaction and the decrease of absorbance at 405 nm was
continuously recorded with a Perkin-Elmer Lamba-25 spectro-
photometer. In this coupled assay method, 1 mol of CO2 was
formed and 1 mol of NADH analog was oxidized under the assay
conditions. An absorption coefficient of 2,410 m
21 was used for
Figure 2. The continuous sedimentation coefficient distribu-
tions of human ODC mutant enzymes in the presence of AZ. The
concentration of ODC was fixed at 0.3 mg/mL with an AZ concentration
of0.03,0.06or0.09 mg/mL(themolarratioofAZ/ODCwas 0.24,0.47and
0.71, respectively). The sedimentation velocity data were globally fitted
with the SEDPHAT program to calculate the Kd values of the ODC-AZ
heterodimer (Table 2). A: ODC_WT; B: ODC_Q119H/V137D/M140E; C:
ODC_7M; D: ODC_7M(-Q119H); E: ODC_7M(-V137D).
doi:10.1371/journal.pone.0026835.g002
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performed with the Sigma Plot 10.0 software program (Jandel, San
Rafael, CA).
Size-distribution analysis by analytical ultracentrifugation
Sedimentation velocity experiments were performed using a
Beckman Optima XL-A analytical ultracentrifuge. Buffer (400 ml)
and sample solutions (380 ml) were loaded into the double sector
centerpiece individually and built up in a Beckman An-50 Ti
rotor. The sedimentation velocity experiments were performed at
20uC with a rotor speed of 42,000 rpm. The protein samples were
followed by continually monitoring UV absorbance at 280 nm
with a time interval of 420 s and a step size of 0.002 cm. Multiple
scans at different time points were fitted to a continuous size
distribution model with the SEDFIT software [63,64]. All of the
size distributions were worked out at a confidence level of p=0.95,
a best fit average anhydrous frictional ratio (f/f0), and a resolution
N of 250 sedimentation coefficients between 0.1 and 20.0 S.
To determine the dissociation constant (Kd) for human ODC
binding toward AZ, sedimentation velocity experiments were
carried out at three different concentrations of AZ (0.03, 0.06 or
0.09 mg/mL) with a constant concentration of human ODC
(0.3 mg/mL). All of the sedimentation data were globally fitted
into the AB hetero-association model using the SEDPHAT
program [65,66] to calculate the Kd value for the ODC-AZ
heterodimer. The partial specific volumes of the proteins, the
solvent densities and the viscosity were calculated by the
SEDNTERP program [67].
Supporting Information
Table S1 Kinetic parameters of the wild-type and
mutant ODC enzymes.
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